Skip to main content

Featured

Washington’s Aims in Iran Remain Steady, Says Hegseth

                                   Hegseth told reporters that the objectives remained to destroy Iran's missile launchers. In a recent commentary, Fox News host Pete Hegseth argued that the United States’ strategic objectives in Iran have remained largely unchanged despite shifting administrations and evolving regional tensions. According to Hegseth, Washington continues to prioritize deterring Iran’s nuclear ambitions, countering its regional influence, and protecting U.S. personnel and allies in the Middle East. Hegseth suggested that while tactics may vary—from diplomatic pressure to targeted military responses—the core goals have stayed consistent for decades. He also emphasized that Iran’s actions, including support for proxy groups and continued nuclear development, keep the region on edge and force U.S. policymakers to maintain a firm posture. His remarks come amid renewed...
Post a Comment
Read more

article

Labels

Alzheimer’s vaccines get a boost from new drug approval

 

After decades of disappointment and controversy, the field of Alzheimer’s disease research has finally seen a breakthrough with the approval of the first drug that targets the underlying pathology of the condition. 

Aducanumab, a monoclonal antibody that clears amyloid plaques from the brain, was granted accelerated approval by the US Food and Drug Administration in June 2021, despite mixed results from clinical trials and objections from some experts. 

The drug’s approval has rekindled interest in other therapeutic approaches that aim to prevent or slow down the progression of Alzheimer’s, such as vaccines that stimulate the immune system to attack amyloid or tau, another protein that accumulates in the brains of people with the disease. 

Several vaccine candidates are currently in various stages of development and testing, and some researchers are optimistic that they could offer a more effective and convenient way to treat Alzheimer’s than infusions of antibodies.


Labels:

Comments

Post a Comment